27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- The European Commission has designated Orphan Medicinal Product status to Ocugen Inc's (NASDAQ: OCGN) OCU400 (AAV5-hNR2E3) to treat both retinitis pigmentosa (RP) and Leber Congenital amaurosis (LCA).
- Orphan medicinal product benefits include protocol assistance, reduced regulatory fees, research grants, and ten years of market exclusivity following regulatory approval.
- This month, Ocugen teamed up with India's Bharat Biotech to co-develop COVID-19 vaccine candidate Covaxin for the U.S. market.
- According to Form DEFA14A, the company proposed an increase in its authorized shares by 95 million.
- Price Action: OCGN is down 15.9% at $7.72 in premarket trading on last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!